Standard BioTools (LAB) Secures $30M From Illumina and Clears Treeline Merger Hurdles

• Standard BioTools has received early termination of the Hart-Scott-Rodino waiting period from the U.S. Federal Trade Commission, removing a critical regulatory obstacle for its pending all-stock merger with Treeline.
• The company finalized a $30 million buyout of contingent payments from Illumina, securing immediate liquidity and terminating future royalty obligations.
• Standard BioTools is divesting its non-core mass cytometry unit to Multiplex Bio, a move designed to streamline the corporate portfolio ahead of the expected late-2026 closing.
• Upcoming Q2 2026 earnings on August 5 will provide the first financial data point under the new fiscal period, with analysts forecasting a slight per-share loss.

Standard BioTools is executing a rapid series of strategic maneuvers to prepare for its combination with Treeline Biosciences, aiming for a close by the end of 2026. The most significant development is the U.S. Federal Trade Commission's early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act . This regulatory clearance eliminates a major procedural hurdle, allowing the all-stock transaction to proceed without further antitrust delays . The merger will position Standard BioTools to focus exclusively on its core spatial biology and proteomics platforms under Treeline’s ownership .

Why did Standard BioTools sell its mass cytometry business?

To streamline its operations and maximize the value of the Treeline merger, Standard BioTools has agreed to sell its mass cytometry business to Multiplex Bio . This divestiture includes the CyTOF and Hyperion product lines, which are considered non-core assets relative to the company's primary growth drivers . The transaction is structured with up to $10 million in consideration, consisting of a $5 million promissory note bearing 6% interest and up to $5 million in contingent milestone payments. Standard BioTools may also extend a working capital loan of up to $10 million to the buyer if third-party financing is unavailable .

Multiplex Bio, a new entity led by industry veterans Michael Johnson, Tom Villani, and Charles Coffman, will assume responsibility for the commercialization of these product lines . The company ensures full continuity of customer relationships, retaining the majority of the technical team and existing service commitments . The business will continue to operate under the Standard BioTools brand and name, preserving market recognition while shifting operational control . This strategic exit allows Standard BioTools to redirect resources toward the merger-driven repositioning and the integration of Treeline’s gene therapy assets .

How does the Illumina settlement impact Standard BioTools' balance sheet?

Concurrently with the asset divestiture, Standard BioTools has secured approximately $30 million in cash from Illumina through a termination and waiver agreement . This payment settles the 2026 earnout and terminates all future royalty rights related to Illumina’s earlier acquisition of Standard BioTools’ SomaLogic business . By converting uncertain future contingent payments into immediate liquidity, the company strengthens its pro forma net cash position. This liquidity boost is critical for determining the exchange ratio in the upcoming Treeline merger .

The settlement also includes the waiver of various royalty and licensing agreements covering SOMAmer-related intellectual property . This move removes future contingent liabilities from Standard BioTools' balance sheet, simplifying the financial contours of the Treeline combination for shareholders . The influx of cash provides a buffer against volatility and supports the company through the integration phase . Investors view this liquidity event as a positive step toward reducing corporate complexity and enhancing balance sheet strength .

What do Q2 2026 earnings and market data reveal about LAB?

Standard BioTools is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, August 5 . The subsequent earnings conference call will take place on Monday, August 10, at 4:30 p.m. ET . Wall Street analysts are forecasting a net loss of $0.01 per share, with total revenue expected to reach approximately $20.8 million . This projection represents a moderate revenue growth compared to the peak seen in the fourth quarter of 2025 .

Historical performance indicates varying degrees of earnings surprises, with a significant positive revenue surprise of 28.61% recorded in Q4 2025 . However, Q1 2026 demonstrated a strong recovery, beating revenue estimates by 18.80% and earnings per share expectations by 14.29% . Market data shows the stock trading at $0.82, up 2.7% for the day, with a market capitalization of $318.54 million . The stock currently trades below its 50-day and 200-day moving averages, suggesting near-term volatility .

Institutional activity reflects shifting sentiment, with Cibc World Markets Corp, Aigen Investment Management LP, and EntryPoint Capital LLC establishing new positions during the fourth quarter . Notably, Russell Investments Group Ltd. expanded its position by nearly 3,000% in the third quarter, now holding 25,021 shares valued at roughly $33,000 . The company’s price-to-earnings ratio stands at 4.05, with a beta of 1.42, indicating higher volatility relative to the broader market . These financial and market dynamics underscore the transitional phase Standard BioTools is navigating as it prepares for the Treeline merger .